Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

EGM Statement

20 Nov 2007 12:08

ReGen Therapeutics PLC20 November 2007 Results of Extraordinary General Meeting ReGen Therapeutics Plc (the "Company") announces that, at the ExtraordinaryGeneral Meeting of the Company held earlier today, Shareholders passed all theresolutions including the resolution relating to the proposed share capitalconsolidation of the Company, as detailed in the circular sent to Shareholdersdated 26 October 2007 (the "Capital Consolidation"). The expected timetable for the Capital Consolidation is as follows: Record Date for Capital Consolidation: 6.00 p.m. on 20 November 2007 Commencement of Dealings in New Ordinary Shares 8.00 a.m. on 21 November 2007 CREST Accounts credited with New Ordinary Shares 21 November 2007 Despatch of certificates for New Ordinary Shares by 27 November 2007 Despatch of cheques for fractional entitlements and certificates for New Ordinary Shares; CREST accounts credited with value of fractional entitlements by 10 December 2007 Application has been made to the London Stock Exchange for the New OrdinaryShares arising on the Capital Consolidation to be admitted to trading on AIM on21 November 2007. Notes: If any of the above times and/or dates change, the revised times and/or dateswill be notified to Shareholders by announcement through a RegulatoryInformation Service. References to time in this announcement and the Notice of Extraordinary GeneralMeeting are to British Time. For further enquiries: Percy Lomax, Chairman and Chief Executive, ReGen Therapeutics Plc Tel: 020 7153 4920 Direct: 020 8504 2156 Mobile: 07932 751541 Roland Cornish, Beaumont Cornish Limited Tel: 020 7628 3396 Nick Bealer, King & Shaxson Capital Limited Tel: 020 7426 5986 Andrew Marshall, Greycoat Communications Tel: 020 7960 6007 Mobile: 07785 297111 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th May 20197:00 amRNS9th Annual LD Micro Invitational
7th May 20197:00 amRNSNotice of AGM
2nd May 20197:00 amRNSDirector/PDMR Shareholding
1st May 20197:00 amRNSUpdate on IND Application
25th Apr 20195:00 pmRNSDirector/PDMR Shareholding
24th Apr 201912:55 pmRNSReissue: Interim Clinical Data
24th Apr 20197:00 amRNSInterim Clinical Data
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
4th Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSIND Application Submitted for NASH Oral Treatment
7th Feb 20197:00 amRNSDirectorate Change
11th Dec 20187:00 amRNSExercise of Warrants & Issue of Equity
3rd Dec 20187:00 amRNSMilciclib HCC Phase IIa Trial Enrollment Completed
28th Nov 20187:00 amRNSForalumab: Phase 1 Trial with Nasal Administration
27th Nov 20187:00 amRNSHolding(s) in Company
26th Nov 20187:00 amRNSStatement re: ADSs
23rd Nov 20185:00 pmRNSClosing of Offering and Total Voting Rights
20th Nov 20187:30 amRNSDiscounted exercise prices of outstanding warrants
20th Nov 20187:00 amRNSOffer Pricing, Nasdaq Listing & Loan Conversion
18th Oct 20187:15 amRNSAmended Registration Statement filed with the SEC
16th Oct 20187:00 amRNSMilciclib synergistic activity presented at AASLD
25th Sep 20187:00 amRNSTiziana announces Offering & Application to Nasdaq
24th Sep 20187:03 amRNSInterim Results for Six Months Ended 30 June 2018
24th Sep 20187:00 amRNSU.S. FDA Approval IND Nasal Foralumab Phase 1
13th Sep 20181:05 pmRNSPDMR Dealing
12th Sep 20187:00 amRNSPDMR dealings
11th Sep 20187:00 amRNSPDMR Dealing
24th Aug 20187:00 amRNSPDMR Dealing
21st Aug 20187:00 amRNSPDMR dealings
20th Aug 20187:00 amRNSPDMR Dealing
17th Aug 20187:00 amRNSPDMR Dealing
16th Aug 20189:00 amRNSFiling of Investigational New Drug application
27th Jul 20187:00 amRNSUS Registration Statement for Proposed Offering
25th Jun 201810:49 amRNSResult of AGM
7th Jun 20187:01 amRNSAppointment of Broker
7th Jun 20187:00 amRNSFinal Results
1st Jun 20187:00 amRNSNotice of AGM
23rd May 20184:40 pmRNSSecond Price Monitoring Extn
23rd May 20184:35 pmRNSPrice Monitoring Extension
16th May 20187:00 amRNSMilciclib Phase 2a Trial - Tolerability Update
1st May 20183:00 pmRNSGrant of Options - Director Dealing
27th Apr 20187:00 amRNSIssue of Equity
19th Apr 20187:00 amRNSSubscription
16th Apr 20187:25 amRNSLicense Agreement
9th Apr 20188:25 amRNSPresentation at ASCO 3 June 2018
5th Apr 20187:00 amRNSAppointment of Broker
4th Apr 20187:00 amRNSAppointment of Director
5th Mar 20187:00 amRNSPlacing to raise £600,000 and issue of equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.